title: RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study.
abstract: OBJECTIVE
  We prospectively investigated the potential usefulness of PET using a new tracer targeting integrin αvβ3 (termed RGD-K5) in patients with head and neck cancer (HNC) undergoing definitive concurrent chemoradiotherapy (CCRT).
  
  
  METHODS
  Newly diagnosed patients with locally advanced HNC scheduled for definitive CCRT were eligible. RDG-K5 PET and FDG PET scans were performed at three different time points (baseline, 2 weeks, and 3 months post-treatment).
  
  
  RESULTS
  Nine patients completed all of the three scans, whereas two patients withdrew after two scans only. Uptake of both RGD-K5 and FDG generally decreased following CCRT. However, the observed decrease did not differ significantly between complete responders and non-responders. At 3 months post-treatment, the uptake of both RGD-K5 and FDG at the main tumors was significantly lower in those who achieved complete responses than in those with residual tumors.
  
  
  CONCLUSIONS
  RGD-K5 PET has the potential to identify patients with incomplete responses to CCRT.
authors.affiliation: Department of Nuclear Medicine, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333.
authors.forename: Shih-Hsin
authors.initials: SH
authors.lastname: Chen
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333.
authors.forename: Hung-Ming
authors.initials: HM
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333.
authors.forename: Chien-Yu
authors.initials: CY
authors.lastname: Lin
authors.affiliation: Department of Radiation Oncology, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333.
authors.forename: Joseph Tung-Chieh
authors.initials: JT
authors.lastname: Chang
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333.
authors.forename: Chia-Hsun
authors.initials: CH
authors.lastname: Hsieh
authors.affiliation: Departments of Otorhinolaryngology, Head and Neck Surgery, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333.
authors.forename: Chun-Ta
authors.initials: CT
authors.lastname: Liao
authors.affiliation: Departments of Otorhinolaryngology, Head and Neck Surgery, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333.
authors.forename: Chung-Jan
authors.initials: CJ
authors.lastname: Kang
authors.affiliation: Clinical Trial Center, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333.
authors.forename: Lan-Yan
authors.initials: LY
authors.lastname: Yang
authors.affiliation: Department of Nuclear Medicine, Chang-Gung Memorial Hospital, Linkou, 5, Fu-Shin St., Kwei-Shan Township, TaoYuan County, Taiwan, 333. yen1110@adm.cgmh.org.tw.
authors.forename: Tzu-Chen
authors.initials: TC
authors.lastname: Yen
mesh_terms: D000328:Adult; D059248:Chemoradiotherapy; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000378:metabolism*; D010865:Pilot Projects; D000072078:Positron Emission Tomography Computed Tomography; D021381:Protein Transport / Q000187:drug effects / Q000528:radiation effects
chemical_list: D039302:Integrin alphaVbeta3; D009842:Oligopeptides; D019788:Fluorodeoxyglucose F18; C047981:arginyl-glycyl-aspartic acid
keywords: CCRT; FDG; Head and neck cancer; Integrin αvβ3; PET; RGD-K5